- cafead Jan 05, 2024 at 10:02: AM
via The gene editing company cited “organizational streamlining” in a Thursday statement announcing plans to focus resources on its priority drug programs.
article source
article source
-
Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page
Intellia to lay off staff, cut some early research
- Thread starter cafead
- Start date
<
Similar threads